What Is a Patent? A Temporary Monopoly in Exchange for Publication
By the BrainSnail editorial team. How these articles are written and checked, and how to tell us when one is wrong.
An inventor with a new process has two options. Keep it secret, which risks losing everything if a competitor works it out or an employee leaves, or publish it in full and receive, in return, a legal right to stop anyone else using it for twenty years. That trade is the whole design of the patent system: the state grants a monopoly, and the price of the monopoly is that the knowledge enters the public record where anyone can read it and everyone can use it once the term expires.
What can be patented
The requirements are consistent across major jurisdictions and each one does real work:
- •Novelty, meaning the invention has not been disclosed anywhere before the filing date, which is why publishing or demonstrating an invention before filing destroys the right in most countries
- •Inventive step, or non-obviousness, meaning it would not have been obvious to a skilled person in the field, which is the requirement that most applications fail on
- •Industrial applicability, meaning it does something useful rather than being a curiosity
- •Sufficient disclosure, meaning the specification must describe the invention well enough that a skilled person could reproduce it, which is the public's side of the bargain and which examiners enforce
- •Excluded categories vary, and generally cover discoveries as distinct from inventions, mathematical methods, scientific theories, aesthetic creations, mental acts and business methods as such, along with anything contrary to public order
- •Software and biotechnology sit at the contested edges, with software patentable in the United States under conditions that have narrowed considerably since a 2014 Supreme Court decision, and in Europe only where it produces a technical effect
How the system runs
An application is filed with a national or regional office, published eighteen months after the earliest filing date whether or not it has been granted, and examined by an examiner who searches the prior art and objects to anything already known or obvious, which produces a correspondence lasting years. The right, once granted, is national: a patent is valid only where it was granted, so international protection means filing in each territory, usually coordinated through an international application that delays the decision and the cost for thirty months. The term is twenty years from filing, and since several of those years are consumed by examination and, in pharmaceuticals, by regulatory approval, the effective commercial life is shorter, which is why extensions exist for medicines. Renewal fees are payable annually and rise steeply, which deliberately prunes patents nobody values. Enforcement is entirely private: the office grants the right and does nothing to police it, so a holder must sue, which is expensive enough that a great many patents held by individuals and small firms are unenforceable in practice.
The argument for and against
The case in favour is that invention is expensive and imitation is cheap, so without protection the imitator undercuts the inventor and the incentive to invest disappears, particularly in industries with high development costs and low copying costs, of which pharmaceuticals is the standard example, with an approved drug costing hundreds of millions to develop and pennies to reproduce. The disclosure requirement is the second argument, since the alternative to patents is trade secrecy, which keeps knowledge out of circulation permanently. The case against is that a monopoly raises prices and restricts access, which is a matter of life and death in medicine, that patent thickets in complex products create so many overlapping rights that developing anything requires negotiating with dozens of holders, that the system is used defensively and litigiously by entities that produce nothing and exist to extract settlements, and that empirical studies linking patent protection to actual innovation rates produce mixed results, with some finding the strongest effect in a small number of industries and little elsewhere.
Where it gets hardest
Medicines concentrate every tension in the system. The twenty-year monopoly funds development and also sets prices far above production cost during the term, which is the mechanism by which antiretroviral drugs were unaffordable across southern Africa during the worst years of the epidemic until a combination of litigation, generic manufacture in India and international pressure changed the position. The intellectual property agreement of the body that governs world trade obliged most countries to grant pharmaceutical patents and includes flexibilities, notably compulsory licensing, which allows a government to authorise generic production in a public health emergency and which several states have used against considerable diplomatic resistance. Evergreening, in which a holder obtains further patents on minor variations to extend effective protection, is policed differently in different jurisdictions, with India's law explicitly refusing patents on new forms of known substances without improved efficacy. The same arguments reappeared over vaccines during the pandemic, and the proposal to waive patent protection produced an agreement so narrow that most observers considered it symbolic.
The takeaway
A patent grants a twenty-year right to exclude others from using an invention, in exchange for publishing it in enough detail that a skilled person could reproduce it, which is the public's side of the bargain. It requires novelty, an inventive step and industrial applicability, is granted country by country, and is enforced only by the holder suing, which makes it expensive to use. It exists because invention is costly and imitation is cheap, and its sharpest costs appear in medicine, where the monopoly that funds development also prices the product out of reach.